Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
BRCA1 and BRCA2 germline mutations
Brazil
Ovarian cancer
Prevalence
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 Jan 2019
03 Jan 2019
Historique:
received:
18
09
2018
accepted:
19
12
2018
entrez:
5
1
2019
pubmed:
5
1
2019
medline:
16
4
2019
Statut:
epublish
Résumé
BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma. However, these variants have not been extensively characterized in patients with ovarian cancer in Brazil. In this retrospective study we evaluated clinical characteristics and BRCA1/2 genetic test results from patients with ovarian carcinoma who underwent genetic counseling at A.C.Camargo Cancer Center (Brazil) between 2015 and 2017 and had performed germline genetic testing of BRCA1/2 genes. Among 158 patients, 33 P and LP variants and were found (20.8%), 27 in BRCA1 and six in BRCA2, and six variants of unknown clinical significance (VUS). Thirteen percent of the patients did not have Multiplex Ligation-dependent Probe Amplification (MLPA) results. Three P variants in BRCA1 were found in more than one patient: c.5266dupC (p.Gln1756Profs*74), c.3331_3334delCAAG (p.Gln1111Asnfs5*), and c.211A > G (p.Arg71Gly). One LP variant in BRCA1 had not been previously described, c.4153_4154delCT (p.Leu1385Ilefs*5). Patients with previous diagnosis of breast cancer were carriers of P or LP variant in 8 of 12 cases (66.7%), and patients with a family history of ovarian or breast cancer in first- or second-degree relatives were carriers of P or LP variant in 26.7% of cases compared to 16.9% for patients without family history (p = 0.166). Prevalence of BRCA1/2 germline P and LP variants is slightly higher than previously described by the largest occidental studies, with a high prevalence of variant c.5266dupC (p.Gln1756Profs*74) in BRCA1 observed. Moreover, we identified a new LP variant.
Sections du résumé
BACKGROUND
BACKGROUND
BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma. However, these variants have not been extensively characterized in patients with ovarian cancer in Brazil.
METHODS
METHODS
In this retrospective study we evaluated clinical characteristics and BRCA1/2 genetic test results from patients with ovarian carcinoma who underwent genetic counseling at A.C.Camargo Cancer Center (Brazil) between 2015 and 2017 and had performed germline genetic testing of BRCA1/2 genes.
RESULTS
RESULTS
Among 158 patients, 33 P and LP variants and were found (20.8%), 27 in BRCA1 and six in BRCA2, and six variants of unknown clinical significance (VUS). Thirteen percent of the patients did not have Multiplex Ligation-dependent Probe Amplification (MLPA) results. Three P variants in BRCA1 were found in more than one patient: c.5266dupC (p.Gln1756Profs*74), c.3331_3334delCAAG (p.Gln1111Asnfs5*), and c.211A > G (p.Arg71Gly). One LP variant in BRCA1 had not been previously described, c.4153_4154delCT (p.Leu1385Ilefs*5). Patients with previous diagnosis of breast cancer were carriers of P or LP variant in 8 of 12 cases (66.7%), and patients with a family history of ovarian or breast cancer in first- or second-degree relatives were carriers of P or LP variant in 26.7% of cases compared to 16.9% for patients without family history (p = 0.166).
CONCLUSION
CONCLUSIONS
Prevalence of BRCA1/2 germline P and LP variants is slightly higher than previously described by the largest occidental studies, with a high prevalence of variant c.5266dupC (p.Gln1756Profs*74) in BRCA1 observed. Moreover, we identified a new LP variant.
Identifiants
pubmed: 30606148
doi: 10.1186/s12885-018-5235-3
pii: 10.1186/s12885-018-5235-3
pmc: PMC6319008
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Références
J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5
pubmed: 10995813
Am J Hum Genet. 2001 Mar;68(3):700-10
pubmed: 11179017
Hum Mutat. 2001 Jun;17(6):520-1
pubmed: 11385711
J Natl Cancer Inst. 2004 Mar 17;96(6):487-8
pubmed: 15026475
Cancer. 2005 Dec 15;104(12):2807-16
pubmed: 16284991
J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706
pubmed: 17148771
J Cancer Res Clin Oncol. 2009 Nov;135(11):1593-9
pubmed: 19499246
Gynecol Oncol. 2011 May 1;121(2):353-7
pubmed: 21324516
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Gynecol Oncol. 2012 Feb;124(2):236-43
pubmed: 22044689
Hered Cancer Clin Pract. 2011 Dec 20;9:12
pubmed: 22185575
J Clin Oncol. 2012 Jul 20;30(21):2654-63
pubmed: 22711857
BMC Womens Health. 2014 Dec 12;14:150
pubmed: 25494812
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Cancer Genet. 2016 Jan-Feb;209(1-2):50-2
pubmed: 26656232
Lancet. 2016 Mar 5;387(10022):945-956
pubmed: 26707054
JAMA Oncol. 2016 Apr;2(4):482-90
pubmed: 26720728
Hered Cancer Clin Pract. 2016 Jan 08;14:1
pubmed: 26753012
Oncologist. 2016 Jul;21(7):832-9
pubmed: 27286788
J Clin Oncol. 2016 Dec;34(34):4071-4078
pubmed: 27621404
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
BMC Cancer. 2016 Dec 3;16(1):934
pubmed: 27914478
J Clin Oncol. 2017 May 1;35(13):1411-1420
pubmed: 28240969
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Int J Gynecol Cancer. 2017 Oct;27(8):1650-1657
pubmed: 28692638
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
PLoS One. 2017 Oct 20;12(10):e0186043
pubmed: 29053726
Breast Cancer Res Treat. 2018 Apr;168(3):695-702
pubmed: 29297111
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
BJOG. 2018 Oct;125(11):1451-1458
pubmed: 29460478
J Gynecol Oncol. 2018 Jul;29(4):e43
pubmed: 29770616
Gynecol Oncol. 2018 Oct;151(1):145-152
pubmed: 30078507